ダウンロード数: 1450
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
58_391.pdf | 658.61 kB | Adobe PDF | 見る/開く |
タイトル: | 尿路上皮癌に対する術前化学療法としてのGC療法の近接効果に関する検討 |
その他のタイトル: | The Effect of Presurgical Gemcitabine Cisplatin Chemotherapy for Urothelial Carcinoma |
著者: | 進藤, 哲哉 北村, 寛 舛森, 直哉 塚本, 泰司 |
著者名の別形: | Shindo, Tetsuya Kitamura, Hiroshi Masumori, Naoya Tsukamoto, Taiji |
キーワード: | Urothelial carcinoma Chemotherapy |
発行日: | Aug-2012 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 58 |
号: | 8 |
開始ページ: | 391 |
終了ページ: | 394 |
抄録: | Neoadjuvant methotrexate, vinblastin, adriamycin and cisplatin (MVAC) chemotherapy is now recommended for muscle invasive bladder cancer. On the other hand, gemcitabine and cisplatin (GC) is often substituted for MVAC in patients receiving neoadjuvant chemotherapy followed by radical cystectomy, although it not clear whether GC has a similar benefit in this setting. We assessed 27 patients who received MVAC or GC as presurgical or neoadjuvant chemotherapy followed by radical surgery from 2007 to 2011. We evaluated adverse events of each chemotherapy and also the pathological T stage of the primary site, which was indicated to be a prognostic factor in previous reports. Ten patients received GC therapy and 17 patients MVAC. Every MVAC patient received 2 courses of chemotherapy, and 2-7 courses of GC (median 3 courses). Only one patient receiving MVAC (5.9%) and 2 patients receiving GC (20%), achieved pT0 there being no significant difference between the two groups. Although the decrease in platelets was greater in the patients receiving GC than in those receiving MVAC, blood transfusion was needed only in the MVAC group. No patient had to postpone the surgery due to side effects from chemotherapy. The effects of the GC regimen at the primary site of urothelial cancer seem to be similar to those of the MVAC regimen. |
著作権等: | 許諾条件により本文は2013-09-01に公開 |
URI: | http://hdl.handle.net/2433/159775 |
PubMed ID: | 23052260 |
出現コレクション: | Vol.58 No.8 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。